New research reveals a drug developed by scientists at Oregon Health & Science University may develop into a new treatment for an especially aggressive form of breast cancer.
A rigorous systematic review of the present state of knowledge on the use of acetaminophen during pregnancy and the risk of specific neurodevelopmental disorders (NDDs), such as autism and ADHD, offers reassurance that acetaminophen does not increase the risk of NDDs.
The human genome is riddled with relics of viral infections—bits of DNA from viruses that have been inserted in human DNA over millions of years and never left. Most are silent but some have taken on functional roles, particularly in organs that evolve relatively rapidly, including the placenta.
Designed as a safe, accessible, and office-based alternative to surgical sterilization, FemBloc represents a paradigm shift in permanent contraception
Pulsenmore announced today that it received FDA de novo clearance for its home-use prenatal ultrasound platform.
Diagnosing heart failure in women can be particularly challenging. New research on biomarkers may lead to more accurate diagnoses for heart failure, in both women and men.
Doctors may be able to spare patients unnecessarily aggressive breast cancer treatments by collecting and testing cancer cells in patients’ blood, research from the University of Michigan and the University of Kansas suggests.
The tool integrates with the current laboratory infrastructure, captures images of embryos and creates an AI score.
FRANKLIN LAKES, N.J., Oct. 22, 2025 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a new self-collection solution for HPV testing in markets outside the United States. This new innovation simplifies at-home sample collection for patients and further automates lab processing using high-tech robotics with the BD COR™ System.
ALLENDALE, N.J., Oct. 22, 2025 /PRNewswire/ — iNPLANT LLC, a leader in surgical innovation, today announced the release of the iNPLANT XL Funnel, a next-generation surgical device designed for the insertion of large breast implants (800cc–1500cc) using the “No-touch” surgical technique. The XL Funnel is the only device engineered specifically for this size range, addressing a critical unmet need in reconstructive and aesthetic breast surgery.